Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Stenzinger

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
ESMO Open|November 24, 2022
COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapyC Pixberg, M Zapatka, M Hlevnjak, et al.
ESMO Open|April 2, 2025
Comprehensive genomic and transcriptomic analysis enables molecularly guided therapy options in peritoneal and pleural mesotheliomaL Möhrmann, M Werner, M Oleś, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2025
ESMO basic requirements for AI-based biomarkers in oncology (EBAI)M Aldea, M Salto-Tellez, A Marra, et al.
ESMO Open|September 4, 2021
Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancerG Mountzios, E Samantas, K Senghas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2023
Erratum to "Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project": [Annals of Oncology 32 (2021) 1626-1636]D M Vega, L M Yee, L M McShane, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 4, 2021
Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization ProjectD M Vega, L M Yee, L M McShane, et al.
Nature Medicine|June 6, 2023
The German Network for Personalized Medicine to enhance patient care and translational researchA L Illert, A Stenzinger, M Bitzer, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing?D William, M Bermúdez, A Kübler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2022
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancersA Jahn, A Rump, T J Widmann, et al.
ESMO Open|January 5, 2021
Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near futureP Hofman, M Ilié, E Chamorey, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
ESMO Open|November 24, 2022
COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapyC Pixberg, M Zapatka, M Hlevnjak, et al.
ESMO Open|April 2, 2025
Comprehensive genomic and transcriptomic analysis enables molecularly guided therapy options in peritoneal and pleural mesotheliomaL Möhrmann, M Werner, M Oleś, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2025
ESMO basic requirements for AI-based biomarkers in oncology (EBAI)M Aldea, M Salto-Tellez, A Marra, et al.
ESMO Open|September 4, 2021
Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancerG Mountzios, E Samantas, K Senghas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2023
Erratum to "Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project": [Annals of Oncology 32 (2021) 1626-1636]D M Vega, L M Yee, L M McShane, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 4, 2021
Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization ProjectD M Vega, L M Yee, L M McShane, et al.
Nature Medicine|June 6, 2023
The German Network for Personalized Medicine to enhance patient care and translational researchA L Illert, A Stenzinger, M Bitzer, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing?D William, M Bermúdez, A Kübler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2022
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancersA Jahn, A Rump, T J Widmann, et al.
ESMO Open|January 5, 2021
Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near futureP Hofman, M Ilié, E Chamorey, et al.
Pageof 7